Baird analyst Andrew Wittmann maintains Cintas (NASDAQ:CTAS) with a Outperform and raises the price target from $440 to $475.
Merck’s KEYTRUDA Shows Improvement in Survival for Early-Stage TNBC Patients
KEYTRUDA® (pembrolizumab) is the first and only immunotherapy-based regimen to show a statistically significant improvement in OS as pre-operative (neoadjuvant) treatment with chemotherapy and then as a single
